Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05834894
Other study ID # 2022-01773
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date January 1, 2010
Est. completion date January 31, 2024

Study information

Verified date May 2023
Source University Hospital, Geneva
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This retrospective monocentric study aims to investigate whether a low muscle mass at ICU admission and its loss over the ICU stay predicts mortality, and in what proportion we can counteract it by nutritional support.


Description:

The study hypothesis is that a low muscle mass at ICU admission, measured at the level of L3 on CT scans performed for clinical routine, and its change over the ICU stay predict the prognosis of the patient, especially the 30-day mortality, that it may at least be partly counteracted by nutritional support and that it is related with higher ICU and hospital costs. The objectives of this retrospective study are to determine: 1. the link between baseline body composition at ICU admission and outcomes, such as 30-day, ICU and hospital mortality and LOS, and infections. If this is confirmed, we aim to evaluate the added values of body composition to ICU severity scores to predict 30-day mortality 2. the link between baseline body composition vs. other locations to predict outcomes 3. the impact of body composition changes on the afore-mentioned outcomes. If this is confirmed, we aim to evaluate the added value of changes in body composition to changes in ICU severity scores to predict 30-day mortality 4. the impact of nutritional support on body composition changes


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 4000
Est. completion date January 31, 2024
Est. primary completion date December 31, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Associations of baseline body composition with clinical outcomes: Adults = 18 yrs, hospitalized in the ICU of the HUG between January 1st 2010 and December 31st 2022 and Abdominal, or thoraco-abdominal CT scan measured 48 hours before to 96 hours after ICU admission in the HUG - Associations of body composition changes with clinical outcomes, nutritional support or medico-economic paratemers: Identical as for the associations of baseline body composition with clinical outcomes and At least one additional CT performed during the hospital stay Exclusion Criteria: - Associations of baseline body composition with clinical outcomes: CT scans of low quality or CT scans performed outside of the HUG or Presence of a documented refusal - Associations of body composition changes with clinical outcomes, nutritional support or medico-economic paratemers: Additionnally: oral nutrition, because we cannot assess the quantity and composition of oral intakes retrospectively

Study Design


Related Conditions & MeSH terms


Intervention

Other:
exposure(s) of interest : intensive care unit
Low muscle mass is highly prevalent at hospital admission, and muscle mass generally decreases during hospital stay, especially in critically-ill patients. We would like to mesure muscle mas in critically ill patients and determine the association between outcomes.

Locations

Country Name City State
Switzerland Laurence Genton Geneva

Sponsors (2)

Lead Sponsor Collaborator
University Hospital, Geneva VBertoniMaluf

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary 30-day mortality Association between skeletal muscle index (SMI) at the L3 vertebra level (psoas + abdominal wall muscles + paraspinal muscles), measured from 48 hours before to 96 hours after ICU admission, with 30-day mortality. 30-day mortality between January 1st 2010 and December 31st 2022.
Secondary Association of baseline body composition at ICU admission with other outcomes Association of Skeletal muscle area (SMA), SMAH (Skeletal muscle area/height), SMD (Skeletal muscle density), IMAT (intermuscular and intramuscular adipose tissue), visceral and subcutaneous adipose tissue at the L3 vertebra level with 30-day mortality Determination of cut-off points of SMI, by sex, below which there is an increased risk of 30-day mortality Added value of body composition to ICU severity scores to predict 30-day mortality Association of baseline SMI, SMA, SMAH, SMD, intermuscular, visceral and subcutaneous adipose tissue at the L3 level, with ICU and hospital mortality and LOS, 30-day ICU readmission, duration of mechanical ventilation and infections 30-day
Secondary Association of baseline SMI at the L3 vertebra level vs. other locations to predict outcomes Associations of SMI at the L3 vertebra level with SMI at the other locations Associations of SMI at the other locations with ICU and hospital mortality and LOS, 30-day ICU readmission, duration of mechanical ventilation and infections Comparison of the associations between muscle mass measured at the different anatomical locations and mortality in order to determine the best prognostic location Day 1 to day 30
Secondary Association of body composition changes with outcomes Association of changes in SMI, SMA, SMAH, SMD, IMAT, visceral and subcutaneous adipose tissue with 30-day mortality, ICU and hospital mortality and LOS, 30-day ICU readmission, duration of mechanical ventilation and infections Added value of changes in body composition to changes in ICU severity scores to predict 30-day mortality Day 30
Secondary Association of body composition changes with nutritional support Association of changes in energy coverage and changes in body composition Association of changes in protein coverage and changes in body composition Day 30
Secondary Association of muscle loss with medico-economical parameters Association of baseline muscle mass and muscle loss in the ICU with ICU and hospital costs Association of muscle loss in the ICU with level of nursing workload Day 30
See also
  Status Clinical Trial Phase
Recruiting NCT06061315 - Effect of Collagen Peptides, in Combination With Resistance Training, on Body Composition and Muscle Strength in Untrained Men N/A
Completed NCT04655547 - Impact on Energy Intake by Implementing Recommended Food Texture Through Dietary Guidance N/A
Completed NCT04074278 - Novel Equations for Estimating Lean Body Mass in Patients With Chronic Kidney Disease
Completed NCT02146612 - Amino Acid Usage Patterns in Daily Practice N/A
Completed NCT04585841 - The Effect of Cannabidiol on Lean Body Mass in Patients Receiving Chemotherapy Phase 1
Completed NCT05890859 - Lean Body Mass in Head and Neck Cancer Patients During Cisplatin-based Chemoradiation N/A